tiprankstipranks
Advertisement
Advertisement

AGIO Stock Latest News

Agios Extends Mitapivat into Pediatric Thalassemia, Opening a New Long-Term Growth Path
Company AnnouncementsAgios Extends Mitapivat into Pediatric Thalassemia, Opening a New Long-Term Growth Path
1d ago
AGIO
Agios Advances Pediatric Mitapivat Trial in Transfusion-Dependent Thalassemia: What Investors Should Watch
PremiumCompany Announcements
Agios Advances Pediatric Mitapivat Trial in Transfusion-Dependent Thalassemia: What Investors Should Watch
1d ago
AGIO
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA
PremiumThe Fly
Agios Pharmaceuticals price target lowered to $40 from $41 at BofA
1d ago
AGIO
Agios will not advance tebapivat in lower-risk myelodysplastic syndromes
PremiumThe Fly
Agios will not advance tebapivat in lower-risk myelodysplastic syndromes
2d ago
AGIO
Agios announces EC grants marketing authorization for PYRUKYND
PremiumThe Fly
Agios announces EC grants marketing authorization for PYRUKYND
8d ago
AGIO
Tessa Romero Reiterates Hold on Agios Pharma as Mitapivat Momentum Balances Competitive and Regulatory Uncertainties
PremiumRatingsTessa Romero Reiterates Hold on Agios Pharma as Mitapivat Momentum Balances Competitive and Regulatory Uncertainties
18d ago
AGIO
Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat
Premium
The Fly
Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat
18d ago
AGIO
Agios Pharmaceuticals to present mitapivat data at EHA Congress
Premium
The Fly
Agios Pharmaceuticals to present mitapivat data at EHA Congress
18d ago
AGIO
Agios Pharmaceuticals Earnings Call Signals Strong Momentum
PremiumCompany Announcements
Agios Pharmaceuticals Earnings Call Signals Strong Momentum
1M ago
AGIO
Agios Pharmaceuticals price target lowered to $36 from $39 at Truist
PremiumThe Fly
Agios Pharmaceuticals price target lowered to $36 from $39 at Truist
1M ago
AGIO
Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)
PremiumThe Fly
Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)
1M ago
AGIO
Is AGIO a Buy, Before Earnings?
PremiumPre-Earnings
Is AGIO a Buy, Before Earnings?
1M ago
AGIO
Agios Pharmaceuticals price target lowered to $41 from $44 at BofA
PremiumThe FlyAgios Pharmaceuticals price target lowered to $41 from $44 at BofA
1M ago
NVO
AGIO
Maintaining Buy on Agios: Mitapivat’s Risk-Adjusted Upside Despite Etavopivat Competition and Regulatory Uncertainty
Premium
Ratings
Maintaining Buy on Agios: Mitapivat’s Risk-Adjusted Upside Despite Etavopivat Competition and Regulatory Uncertainty
1M ago
AGIO
Agios Pharmaceuticals: Mitapivat’s Early-Mover Advantage and Diversified Pipeline Support Buy Rating Despite Emerging Sickle Cell Competition
Premium
Ratings
Agios Pharmaceuticals: Mitapivat’s Early-Mover Advantage and Diversified Pipeline Support Buy Rating Despite Emerging Sickle Cell Competition
1M ago
AGIO
H.C. Wainwright cuts Agios target on smaller market post Novo data
PremiumThe Fly
H.C. Wainwright cuts Agios target on smaller market post Novo data
1M ago
NVO
AGIO
Agios Pharmaceuticals falls -23.4%
PremiumThe Fly
Agios Pharmaceuticals falls -23.4%
1M ago
AGIO
Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia
PremiumThe Fly
Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia
1M ago
BX
DX
Agios Pharmaceuticals falls -23.7%
PremiumThe Fly
Agios Pharmaceuticals falls -23.7%
1M ago
AGIO
Agios sinks after Novo Nordisk reports sickle cell data
PremiumThe FlyAgios sinks after Novo Nordisk reports sickle cell data
1M ago
NVO
AGIO
Agios could come under pressure off Novo Nordisk headline, says Truist
Premium
The Fly
Agios could come under pressure off Novo Nordisk headline, says Truist
1M ago
NVO
AGIO
Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan
Premium
The Fly
Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan
2M ago
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >